HOME >> MEDICINE >> NEWS
VELCADE (Bortezomib) receives European marketing authorisation

ghted that marketing authorisation for VELCADE has been granted, as it is the first major advance for patients with multiple myeloma in more than a decade, and marks the company's commitment to Oncology." said Ken Watters, European Medical Director, Ortho Biotech.

"The approval of VELCADE today brings renewed hope to thousands of European multiple myeloma patients and their families" said Eric Low, Executive Director, International Myeloma Foundation (UK). "The multiple myeloma advocacy community has campaigned tirelessly over the years for cutting edge treatments such as VELCADE to be made available to patients, this is a very proud day", he continued.

The findings of a pre-specified interim analysis from an ongoing phase III trial which compared VELCADE to dexamethasone in refractory multiple myeloma patients found a statistically significant improvement in time to disease progression the primary endpoint of the trial in patients receiving VELCADE compared to patients receiving high-dose dexamethasone. Patients in the control arm of the trial were given the opportunity to switch to VELCADE as soon as possible based on an interim analysis that found a statistically significant improvement in TTP in patients receiving VELCADE compared to patients receiving dexamethasone.

VELCADE has a generally predictable, manageable safety profile (with appropriate monitoring and if necessary, dose modification). VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. There are approximately 50 ongoing clinical trials (in Europe and the US) investigating the potential of VELCADE in all stages of multiple myeloma and other cancers.

A single licence has been granted to market VELCADE in the 15 member states of the EU, plus Norway and Iceland. In addition it will be available in the 10 accession countries.

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Ph
'"/>

Contact: Eva Reynolds
eva_reynolds@uk.bm.com
44-20-7831-6262
Burson-Marsteller
28-Apr-2004


Page: 1 2 3

Related medicine news :

1. VELCADE(TM) data confirms long-term survival
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
(Date:7/31/2014)... have learned that recent fears of invasive lionfish causing ... to control lionfish by fishing derbies and targeted fisheries ... And there,s a simple way to know for sure ... it,s been cooked. , Pacific lionfish were first reported ... have been gaining swiftly in number ever since. They,re ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Setting goals for ... on blogs on successful tips to weight loss. Fitness on ... for over 8 years, and has worked with 6000 customers ... “We have had the chance to monitor why customers start ... exercising, how long they stick to their program, whether or ...
(Date:7/31/2014)... July 31, 2014 Millions of people ... have had traumatic experiences as a child and some ... work. As a highly experienced NJ cosmetic dentist, ... anxiety during their dental procedure. To help these ... team at Champagne Smiles offer several sedation dentistry techniques. ...
(Date:7/31/2014)... Cape Coral, FL (PRWEB) July 31, 2014 ... the opportunity to take charge of their financial future. ... training for women, has opened registration for 6 upcoming ... designed by women, for women, and with input from ... (Rich Woman and It’s Rising Time) who is passionate ...
(Date:7/31/2014)... July 31, 2014 Dr. Andrew Lian-Jie ... Board of Dermatology, fellowship trained Mohs surgeon that has ... Docs. , After extensive dermatology research training at the ... Dr. Li completed his internship in internal medicine at ... of Pennsylvania in Philadelphia. Dr. Li pursued further training ...
Breaking Medicine News(10 mins):Health News:Invasive lionfish likely safe to eat after all 2Health News:Invasive lionfish likely safe to eat after all 3Health News:Fitness on the Go's Rewards Program Helps Clients Reach Their Goals 2Health News:Champagne Smiles is Thrilled to Now Offer Sedation Dentistry to their Patients 2Health News:The Independent Woman to Offer Financial Workshops in the Los Angeles Area - Developed by Women for Women 2Health News:NJ Top Docs Proudly Presents Approved Provider, Dr. Andrew Li of Warren Skin Care Center 2
(Date:7/31/2014)... , July 31, 2014 Touro University ... has been selected as the recipient of a $150,000 ... will allow the University to increase research and classroom ... creating state-of-the-art technology for the study of health sciences, ... the diverse needs and interests of our students," said ...
(Date:7/31/2014)... SAN FRANCISCO , July 31, 2014 /PRNewswire/ ... ) and Aspira Scientific ( Milpitas, California ... joint venture to develop and commercialize new fluorination ... biologically active molecules has benefited from the use ... metabolism, and combine lipophilicity with polarity to improve ...
(Date:7/31/2014)... ANTWERP, Belgium and LONDON , July ... Organization (CRO) and services provider for the medical industries, announced today ... The United Kingdom has one ... valued at USD 8.9 billion in 2012 and it is projected ... was estimated at USD 234 billion in 2012, equal to 9.5% ...
Breaking Medicine Technology:Touro University California Garners Grant From Long Foundation 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2genae Opens Offices in London 2
Cached News: